Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials
| Autor: | Kurt Quitzau, Christine Espinola-Klein, Marius Jankowski, Seyed Hamidreza Mahmoudpour, Luca Valerio, Stavros Konstantinides, Stefano Barco, Christian Becker |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Injections Subcutaneous MEDLINE lcsh:Medicine chemical and pharmacologic phenomena Placebo Article law.invention 03 medical and health sciences Clinical Trials Phase II as Topic 0302 clinical medicine Randomized controlled trial law Neoplasms Internal medicine Recombinant interleukin-2 Humans Medicine Drug safety lcsh:Science Adverse effect Randomized Controlled Trials as Topic Multidisciplinary Dose-Response Relationship Drug Adverse effects business.industry lcsh:R Absolute risk reduction Cancer medicine.disease Recombinant Proteins Treatment Outcome 030104 developmental biology Clinical Trials Phase III as Topic Immune System Diseases Meta-analysis Interleukin-2 lcsh:Q business 030217 neurology & neurosurgery |
| Zdroj: | Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-019-43530-x |
| Popis: | Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of some subtypes of cancer; however, severe adverse events, including venous thromboembolism (VTE), may complicate its administration. Low-dose subcutaneous rIL-2 is being studied for the management of immune-mediated diseases, since it can modulate the immunological response by specifically targeting T regulatory (Treg) cells; importantly, it is supposed to cause fewer or no complications. In this systematic review and meta-analysis of phase II-III randomized controlled trials (RCTs), we investigated the safety of low-dose ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|